These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 11956105)

  • 21. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
    Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
    J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.
    Cosma MP; Panariello L; Quadro L; Dathan NA; Fattoruso O; Colantuoni V
    Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):397-400. PubMed ID: 8670046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
    De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M
    Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation.
    Hayashi Y; Iwashita T; Murakamai H; Kato Y; Kawai K; Kurokawa K; Tohnai I; Ueda M; Takahashi M
    Biochem Biophys Res Commun; 2001 Mar; 281(3):682-9. PubMed ID: 11237712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Dok1 in cell signaling mediated by RET tyrosine kinase.
    Murakami H; Yamamura Y; Shimono Y; Kawai K; Kurokawa K; Takahashi M
    J Biol Chem; 2002 Sep; 277(36):32781-90. PubMed ID: 12087092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.
    Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M
    Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
    Bongarzone I; Vigano E; Alberti L; Borrello MG; Pasini B; Greco A; Mondellini P; Smith DP; Ponder BA; Romeo G; Pierotti MA
    Oncogene; 1998 May; 16(18):2295-301. PubMed ID: 9620546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
    Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of amino acids surrounding tyrosine 1062 in ret in specific binding of the shc phosphotyrosine-binding domain.
    Ishiguro Y; Iwashita T; Murakami H; Asai N; Iida K; Goto H; Hayakawa T; Takahashi M
    Endocrinology; 1999 Sep; 140(9):3992-8. PubMed ID: 10465268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes.
    Xing S; Smanik PA; Oglesbee MJ; Trosko JE; Mazzaferri EL; Jhiang SM
    Endocrinology; 1996 May; 137(5):1512-9. PubMed ID: 8612479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
    Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
    Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
    Iwashita T; Kato M; Murakami H; Asai N; Ishiguro Y; Ito S; Iwata Y; Kawai K; Asai M; Kurokawa K; Kajita H; Takahashi M
    Oncogene; 1999 Jul; 18(26):3919-22. PubMed ID: 10445857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.
    Bocciardi R; Mograbi B; Pasini B; Borrello MG; Pierotti MA; Bourget I; Fischer S; Romeo G; Rossi B
    Oncogene; 1997 Nov; 15(19):2257-65. PubMed ID: 9393871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.
    Iwashita T; Murakami H; Kurokawa K; Kawai K; Miyauchi A; Futami H; Qiao S; Ichihara M; Takahashi M
    Biochem Biophys Res Commun; 2000 Feb; 268(3):804-8. PubMed ID: 10679286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation.
    Kato M; Iwashita T; Akhand AA; Liu W; Takeda K; Takeuchi K; Yoshihara M; Hossain K; Wu J; Du J; Oh C; Kawamoto Y; Suzuki H; Takahashi M; Nakashima I
    Antioxid Redox Signal; 2000; 2(4):841-9. PubMed ID: 11213488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell signalling and gene expression mediated by RET tyrosine kinase.
    Kurokawa K; Kawai K; Hashimoto M; Ito Y; Takahashi M
    J Intern Med; 2003 Jun; 253(6):627-33. PubMed ID: 12755958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
    Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
    Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.
    Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
    Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
    Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
    Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
    Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.